TSLP induction in high CRLF2-expressing and JAK2-mutated B-ALL is known to activate STAT5 and PI3K/mTOR pathways [27], and this insight is exploited in innovative new therapeutic approaches that are currently clinically trialed [6]. The gene discussed is JAK2; the disease is precursor B-cell acute lymphoblastic leukemia.